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Other names: sv0-MUC4 
Location: 3q29 
Note: MUC4 belongs to the human mucin family, and 
more specifically to the subgroup of the membrane-
anchored mucin. It is an O-glycoprotein that can extend 
up to 2 micrometer over the cell membrane. It is 
suggested that MUC4 is translated as a single precursor 
polypeptide, which is further cleaved at a GDPH site in 
two subunits, MUC4a and MUC4b. MUC4a is the 
mucin type subunit and MUC4b is the membrane-
bound growth factor like subunit. Both subunits remain 
non-covalently associated. MUC4 is also found in 
several secretions such as in the milk. MUC4 along 
with other mucins is part of the mucus, the viscous gel 
that covers, moisturizes, and protects all epithelial 
surfaces. 
DNA/RNA 
Note: MUC4 gene is located on the chromosome 3 in 
the region q29, oriented from telomere to centromere 
and clustered with another mucin gene MUC20. MUC4 
is highly polymorphic, harboring numerous sequences 
repeated in tandem and presenting variable number of 
tandem repeat (VNTR) polymorphism. The sequence 
repeated in tandem is localized in exon 2 and is 
composed of a 48 bp repetitive unit. Due to this highly 
variable region 27 distinct alleles have been identifi d 
for MUC4. Among these, three alleles represent 78.6% 
of all alleles detected: the 19 kb, 10.5 kb, and 15 kb 
that present a prevalence of 47%, 18%, and 13.6 % 
respectively. In addition, 24 alternatively splice 
transcripts have been identified for MUC4 gene, coding 
for membrane-anchored and secreted forms. 
Description 
MUC4 gene spans on a 70 kb-long DNA fragment 
located in 3q29 at the position 196959310-197023545. 
This position varies from individual to individual due 
to VNTR polymorphism of several sequences repeated 
in tandem. The largest domain repeated in tandem is 
localized in exon 2 and is composed of a motif of 48 
bp, repeated up to 400 times. This domain varies from 
7 to 19 kb. Three other sequences repeated in tandem 
with a motif of 15 bp, 26 to 32 bp and 32 bp are 
positioned in introns 3, 4, and 5 respectively. Theses 
sequences present also VNTR polymorphism. 
Various SNPs are reported for MUC4 coding sequence; 
however, either VNTR or SNP polymorphism have 
been associated with specific physiological condition or 
disease. 
Transcription 
MUC4 is transcribed in at least 24 distinct splice 
variant forms in normal and malignant human tissues. 
Twenty-two of these variants are generated by 
alternative splicing of the exons at the 3'-extremity and 
are referred sv1- to sv21-MUC4. Two splice forms are
generated by alternative splicing of exon 2 and are 
called MUC4/X and MUC4/Y. So far, it is unknown if 
these splice forms are translated, however their 
deduced amino acid composition leads to secreted and 
membrane-anchored proteins. The main isoform of 
MUC4 (up to 27.5 kb in size), referred to as sv0-
MUC4, encodes for full-length MUC4 protein. 
MUC4 5'-flanking region (over 3.7 kb upstream of the 
first ATG) has been characterized.  
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A: Schematic representation of MUC4 gene and mRNA. The representation is not drawn to scale. 
B: Example of VTNR polymorphism associated with MUC4 gene. The gDNA of 18 healthy individuals was extracted from the PBMCs 
and digested by ECORI and PstI endonucleases. Southern blot was hybridized with [32] P-radiolabeled probes of each sequence 
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Two transcriptionally active units drive MUC4 
expression. The proximal promoter is TATA-less, 
possesses a transcription initiation site at -199, and is 
mainly composed of GC-rich domains that are potential 
binding sites for Sp1 and the CACCC box binding 
protein. Furthermore, a very high density of binding 
sites for factors known to initiate transcription i
TATA-less promoters (Sp1, CACCC box, GRE, AP-1, 
PEA3 and Med-1) was found within that promoter. The 
distal promoter is flanked by a TATA box located at -
2672/-2668 and three transcriptional initiation site  at -
2603, -2604 and -2605. Responsive regions and cis-
elements for transcription factors involved in Protein 
Kinase A, Protein Kinase C, cAMP signaling pathways, 
in inflammation (NF-kB) and in intestinal (HNF-1, 
HNF-3, HNF4A, GATA4, GATA-6, CDX1, CDX2) 
and respiratory (TITF1, GATA-6, HNF-3b) epithelial 
cell differentiation have also been identified. 
Altogether, these results suggest that MUC4 
transcription is complex, tightly regulated and involves 
many signaling pathways. 
Protein 
Note: MUC4 is a high molecular weight O-
glycoprotein. Molecular weight for precursor full-
length MUC4 protein may range between 550-930 kDa 
depending upon the VNTR polymorphism.  
Classically, the protein moiety represents 20% of the 
mucin mature molecular weight, leading to a fully 
glycosylated protein of 4,650 kDa. 
Description 
MUC4 is synthesized as a precursor cleaved in two 
subunits that remain non-covalently link to each oter: 
the mucin type subunit MUC4a of 850 kDa and the 
membrane-bound growth factor like subunit MUC4b of 
80 kDa. MUC4 is a modular protein, composed of very 
distinct domains. 
MUC4a is rich in serine, threonine, and proline 
residues and present a central domain composed of 16
amino acids repeated in tandem up to 400 times. This
repetitive domain is the hallmark of the mucin family. 
The carboxy-extremity of MUC4a harbors a NIDO and 
an AMOP domain. The NIDO domain is a domain 
identified in the nidogen protein and present in several 
proteins such as the tumor endothelial marker TEM7. 
TEM7 plays a role in angiogenesis via its NIDO 
domain. The AMOP domain (adhesion-associated 
domain in MUC4 and other proteins) is suggested to 
have a role in cell adhesion. In addition to the AMOP 
and NIDO domains, analysis of the MUC4a sequence 
reveals a high degree of similarity with a von 
Willebrand factor (vWF) D domain. However, none of 
the cysteine residues that characterized a vWF D 
domain are conserved in the MUC4 sequence. 
The MUC4b subunit contains two domains rich in N-
glycosylation sites, 3 EGF-like domains, a 
transmembrane sequence, and a small 22 amino acids 
long cytoplasmic tail. 
Expression 
MUC4 expression is developmentally regulated. In 
normal physiologic conditions, MUC4 is expressed in 
the epithelium of the respiratory, digestive and 
urogenital tracts, with level that varies from tissue to 
tissues. In the respiratory tract, MUC4 is strongly 
expressed in the trachea and the lung. In the digestive 
tract, its main pattern of expression is the oesophagus 
and the colon. However, MUC4 is not expressed by the 
annex of the digestive tract such as the liver, the 
pancreas, and the gallbladder. MUC4 is also expressed 
by the epithelial cells of the ocular and auditory 
systems. 
MUC4 is overexpressed or aberrantly expressed in 
several diseases, such as inflammatory bowel disease  
(Crohn or ulcerative colitis) and malignancy. For 
instance, MUC4 is overexpressed in lung, oesophagus, 
and colon cancer and is aberrantly expressed in 
pancreatic cancer. Neoexpression of MUC4 is observed 
early in precancerous pancreatic intraepithelial 
neoplastic lesions that further correlates with the 
disease progression stages. 
Many studies has been conducted on human pancreatic 
or other cancer cell lines in order to elucidate molecular 
mechanisms responsible for aberrant expression of 
MUC4 in diseased condition. Initial studies about 
MUC4 transcriptional regulation showed that Sp1 and
Sp3 were important regulators of MUC4 basal 
expression. EGF and TGF-b growth factors and PKC 
signaling pathway stimulation results in up regulation 
of the promoter activity. Whereas TNF-a and IFN-g 
inflammatory cytokines alone had no effect on MUC4 
transcriptional activity, a strong synergistic effect 
between IFN-g and TNF-a or IFN-g and TGF-b was 
observed. Activation by IFN-g was then showed to be 
mediated by STAT-1. More recently, Th1 (IL-2) and 
Th2 (IL-12, IL-10) cytokines were shown to interfere 
with pancreatic tumorigenic environment and possibly 
modulate MUC4 expression. Subsequent studies aimed 
at deciphering MUC4 regulation by TGF-b pathway 
showed that it could be either Smad4-dependent, 
Smad4-independent (MAPK, PKA, PKC). Retinoic 
acid induced MUC4 expression was mediated by TGF-
b2 and involved RAR-a. TGF-b2 expression in vivo also 
correlated with that of MUC4 in pancreatic tumors. 
Interestingly, recent data have shown that MUC4 is 
negatively regulated by cystic fibrosis transmembrane 
regulator (CFTR), a chloride channel that is defectiv  
in CF. 
In oesophageal cancer cells, MUC4 is regulated by bile 
acids via activation of phosphatidylinositol 3-kinase 
pathway or activation of HNF-1a. 
Studies in lung adenocarcinoma cell lines focused on 
cytokines involved in airway inflammation showed that 
MUC4 is regulated by IL-4 via JAK-3 and IL-9. 
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A: Schematic representation of the modular structure of MUC4. 
B: Schematic representation of MUC4 protein. The representation is not drawn to scale. 
 
Identification of the molecular mechanisms governing 
MUC4 expression will be very informative to assign 
direct roles to that mucin in carcinogenesis and on the 
biological properties of the tumor cell and should 
provide new tools in the future for therapeutic 
intervention. 
Localisation 
In normal physiologic situation, MUC4 is localized in 
the membrane at the apical region of the cells and in 
the mucus secretion. During cancer development, 
MUC4 exhibits diffuse expression in both the 
membrane and cytoplasm. Furthermore, due to loss of 
cell polarity, defined apical localization of MUC4 is
disrupted. 
Function 
MUC4 transmembrane mucin is a highly glycosylated 
protein with an extended rigid extracellular domain that 
may confer a role for MUC4 as a molecular sensor 
between the extracellular milieu and the epithelial cel . 
MUC4 is also the putative ligand of ERBB2 oncogenic 
receptor and thus may participate in cell signalling, 
influence cell proliferation, tumor progression, tumor 
cell morphology, cell polarity and escape to immune 
surveillance. Moreover, its over-expression in 
numerous cancers (lung, oesophagus, intestine, 
pancreas, etc.) is often associated with a poor 
prognosis. Functional role of MUC4 in pancreatic 
tumor growth and metastasis has also been recently 
demonstrated. 
MUC4 consists of two subunits, the extracellular highly 
glycosylated mucin subunit (MUC4-a) and a 
transmembrane subunit containing three EGF-like 
domains (MUC4-b). These subunits of MUC4 may 
confer diverse functions to MUC4. The large sized 
extracellular subunit may provide the anti-adhesive or 
adhesive functions. The anti-adhesive function of 
MUC4 may aid in loosening the tumor cell-ECM 
interactions and facilitating the dissemination of tumor 
cells. Whereas, the high degree of glycosylation present 
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in tandem repeat domain of MUC4 mucin can help in 
the adhesion of tumor cells to secondary sites and 
hence promote metastasis. 
Another important function provided by MUC4 mucin 
is modulation of HER-2/ERBB2 mediated signaling. 
MUC4, an interaction partner of the proto-oncogene 
HER2, induces its localization at the cell membrane 
and triggers the signaling pathways downstream to 
HER-2 activation. The consequences of such 
interactions and signaling activation lead to malignant 
transformation. Hence, dysregulation of MUC4 
expression, a protective cell surface protein, may h ve 
deleterious effects. The association of MUC4 with 
ERBB2 involves its translocation from the basolaterl 
toward the apical membrane and increasing the 
membrane stability. Regulation of MUC4 and ERBB2 
by PEA3 transcription factor was found to be 
conversely correlated, stressing the fact that balance 
between MUC4 and ErbB2 will orientate the tumor cell
toward either differentiation or proliferation. 
Under normal physiological conditions, MUC4 
provides protection, lubrication and moisturization to 
the epithelial surfaces by trapping the foreign particles 
and preventing their accessibility to the cells. Being 
expressed in fetus tissue before differentiation, MUC4 
is also suggested to play role in morphogenic functio s. 
Homology 
Several orthologues of MUC4 are totally or partially 
characterized. Mouse (mMuc4) and rat (rMuc4 or SMC 
for sialomucin complex) are fully identified and present 
60 to 70% homology with human MUC4. Mouse 
mMuc4 is localized on the chromosome 16. Partial 
cDNA sequences of porcine, chinchilla, monkey, and 




Worldwide, pancreatic cancer is the eleventh most 
common cancer and the fourth leading cause of cancer 
related death among men and women. Pancreatic 
cancer presents a 5-years survival rate of 5%. The 
incidence and age-adjusted mortality rate are almost 
equal, underscoring the aggressive nature of the 
disease. 
Prognosis 
The DU-PAN-2 antibody that recognizes a tumor-
associated antigen carries by the MUC4 protein is in 
clinical used in Japan for diagnostic of pancreatic 
adenocarcinoma. MUC4 is aberrantly expressed by 
80% of the adenocarnicoma of the pancreatic gland 
while not expressed in the normal pancreas or in 
pancreatitis. In addition, MUC4 is expressed early in 
the onset of pancreatic cancer, already detected in the 
pancreatic intraepithelial neoplasia (PanIN) of stage I. 
Oncogenesis 
In in vivo model, MUC4 was shown to promote tumor 
progression and metastasis. On clinical sample, patients 
negative for MUC4 expression has a better prognosis 
and a longer life time. 
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